mayaro virus O'nyong'nyong virus Mayaro Virus E2 protein

O’nyong’nyong VLP

AnalyteO'nyong'nyong Virus VLP (Capsid, E1, E2)
Product TypeRecombinant protein expressed in HEK293 cells
Protein Conc.0.1-0.5mg/ml
Product CodeREC31626
Vial Size100ug | 500ug

From: $878.85

SKU: REC31626 Categories: ,

Product Description

O’nyong’nyong Virus VLP (Virus-Like Particle) is a unique product that has been developed in response to the need for high purity, properly assembled and glycosylated O’nyong’nyong virus antigens for use in the development of O’nyong’nyong virus diagnostic.  O’nyong’nyong VLP is produced in human cell lines using state-of-the-art expression techniques. The Native Antigen Company O’nyong’nyong VLP is constructed from E1, E2 and C proteins. Concentration and purification is then performed by a series of ultracentrifuge and chromatographical methods which result in VLPs of exceptional quality and purity.

Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivoand whilst they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others.

O’nyong’nyong virus (ONNV) is a single stranded, positive sense RNA virus that belongs to the genus Alphavirus, a member of the Togaviridae family of viruses. It is closely related to members of the Semliki Forest antigenic sero-complex, a serological group within the Alphavirus genus, including Chikungunya virus (CHIKV), Mayaro virus and Ross River virus. Initially, ONNV was thought to be a strain of CHIKV but phylogenetic studies have shown that the two viruses are distinct (Powers, AM). Two major clades of ONNV have been identified (Rezza, G).Unlike the closely related CHIKV, ONNV is restricted to the African continent.

Currently, there is no antiviral therapy for the treatment of symptomatic cases of ONNV, and no licensed prophylactic vaccine to prevent ONNV infection. Diagnosis of ONNV in humans is achieved using clinical criteria and serological methods to measure O’nyong’nyong specific IgM levels of infected patients.   O’nyong’nyong VLPs may be of value as antigens within immunoassays for the detection of serological responses to infection.



Powers AM, Brault AC, Tesh RB, Weaver SC.2000. Re-emergence of Chikungunya and O’nyong-nyong virus: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol. 2000 Feb;81(Pt 2):471-9.

Rezza G, Chen R, Weaver SC.2017. O’nyong-nyong fever: a neglected mosquito-borne viral disease. Pathog Glob Health. Sep;111(6):271-275.

Centers for Disease Control and Prevention. Letters: O’nyong-nyong Virus Infection Imported to Europe from Kenya by a Traveler. Volume 20, Number 10—October 2014

  CofA REC31626-VLP-100 Batch 1806221546P